Menu
Menu
Le invitamos a participar en este exclusivo encuentro que reunirá a expertos y líderes clínicos para explorar los avances más recientes en medicina de precisión y genómica aplicada.
El evento contará con la participación del Presidente de SOPHiA GENETICS, quien compartirá la visión global de la compañía, así como con especialistas que abordarán el impacto de NGS en hemato-oncología y las tendencias futuras del área.
Asimismo, el evento destacará experiencias reales de clientes que compartirán su práctica clínica utilizando la plataforma SOPHiA DDM™, ofreciendo una perspectiva concreta sobre su impacto en el diagnóstico y la toma de decisiones.
A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Savoy Hotel
Date: 21 de abril
Time: 19:00 - 22:00
19:00 – 19:30
Leading Innovation to Impact: SOPHiA GENETICS’ Global Vision
Ross Muken, President, SOPHiA GENETICS
19:30 – 20:00
Panel NGS para LLC: implementación y validación analítica.
Mauro García-Montenegro
Jefe Anatomia Patologia, Argenetics
20:00 - 20:30
Paneles de genes mediante NGS: Transformando el estudio de las neoplasias mieloides
Andrea Bender, Especialista en Bioquímica Clínica Laboratorio de Especialidades Bioquimicas (LEB)
20:30 – 21:00
What’s Next in Hemato-Oncology Genomics
Bruno Piovezan, Subject Matter Expert LATAM, SOPHiA GENETICS
21:00 – 22:00
Cocktails & Networking
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
